You are here

Esanex Inc

Esanex Has Successful Ph II Meeting with FDA Meeting for SNX-5422 Upcoming Trial in Neuroendocrine Tumors

CP Wire

Thu, 10/4/18 - 09:44 am

neuroendocrine tumors

Esanex Has Successful Ph II Meeting with FDA Meeting for SNX-5422 Upcoming Trial in Neuroendocrine Tumors

Thu, 10/4/18 - 09:28 am

neuroendocrine tumors

Pharma startup led by Lilly Ventures execs raises $4.6 million

MedCity News

Sat, 05/5/12 - 02:11 pm